ChemoCentryx, Inc. (CCXI) News
Filter CCXI News Items
CCXI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CCXI News Highlights
- CCXI's 30 day story count now stands at 1.
- list("500 - Internal server error")
- The most mentioned tickers in articles about CCXI are CC, III and LINK.
Latest CCXI News From Around the Web
Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
ChemoCentryx to Host Virtual R&D Day on April 14, 2021MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET. The event will feature a panel of key opinion leaders, a testimonial from a patient living with ANCA-associated vasculitis and members of the ChemoCentryx Management team. The event will focus on the Company’s upcoming milestones and developments in key pipeline programs. Presenters: Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryxTausif (“Tosh”) Butt, Executive Vice President and Chief Operating Officer of ChemoCentryxDavid Jayne, M.D., Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital in CambridgePeter A. Merkel, M.D., MPH, Chief of Rheu... |
ChemoCentryx, Inc.'s (NASDAQ:CCXI) Profit OutlookChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to... |
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales MissChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales. |
ChemoCentryx Inc (CCXI) Q4 2020 Earnings Call TranscriptImage source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI)Q4 2020 Earnings CallMar 1, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to the ChemoCentryx Fourth Quarter and Full Year 2020 Financial Results Conference Call. |
ChemoCentryx Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysisChemoCentryx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |
ChemoCentryx (CCXI) Reports Q4 Loss, Misses Revenue EstimatesChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? |
ChemoCentryx: Q4 Earnings InsightsShares of ChemoCentryx (NASDAQ:CCXI) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 65.38% year over year to ($0.43), which missed the estimate of ($0.33). Revenue of $4,358,000 decreased by 56.62% from the same period last year, which missed the estimate of $7,990,000. Outlook ChemoCentryx hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Mar 01, 2021 View more earnings on CCXI Time: 05:00 PM ET Webcast URL: https://edge.media-server.com/mmc/p/kdazo5ac Recent Stock Performance 52-week high: $70.29 52-week low: $30.72 Price action over last quarter: Up 19.97% Company Description ChemoCentryx Inc is a biopharma... |
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E.U. (decision expected in H2 2021) and Japan -- -- Topline data from AURORA Phase II clinical trial of avacopan in Hidradenitis Suppurativa (HS) leads to Company plans for Phase III trial of avacopan in patients with most severe form of HS -- -- Topline Results of ACCOLADE Phase II clinical trial of avacopan in C3 Glomerulopathy (C3G) include improved estimated Glomerular Filtration Rate (eGFR); Company plans to discuss evidence of clinical benefit with FDA -- -- Novel orally administered checkpoint inhibitor CCX5... |
ChemoCentryx, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 1, 2021 / ChemoCentryx, Inc. (NASDAQ:CCXI) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 5:00 PM Eastern Time. |
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s effects on kidney function, patient Quality of Life, and reduction in overall glucocorticoid-related toxicities also described -- -- NDA for avacopan in ANCA-Associated Vasculitis is under review by the FDA with a PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that The New England Journal of Medicine (NEJM) has published results from ADVOCATE, the pivotal Phase III study evaluating avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-n... |